2025-12-25 - Analysis Report
Okay, here's a comprehensive analysis of UnitedHealth Group (UNH) based on the provided data.

**0) Report Structure:**

We'll start with the raw data points and then follow with an analysis of each section. Finally, we'll provide a comprehensive summary.

**1) Return Rate Comparison:**

*   **Ticker:** UNH
*   **Company Overview:** UnitedHealth Group is a diversified healthcare company providing health benefits and services.
*   **UNH Cumulative Return:** -18.396%
*   **S&P 500 (VOO) Cumulative Return:** 100.884%
*   **Divergence:** -119.3 (Range: -130.7 to 36.3)
*   **Relative Divergence:** 6.8 (This indicates the current divergence is near the lowest end of its historical range).

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2015-2017  | 58.0%   | 66.4%  | 30.0%   | 0.1   | 199.8  |
| 2016-2018  | 41.0%   | 70.4%  | 26.0%   | 0.1   | 225.8  |
| 2017-2019  | 36.0%   | 73.8%  | 14.0%   | 0.2   | 266.4  |
| 2018-2020  | -43.0%  | 81.2%  | -67.0%  | 0.5   | 317.8  |
| 2019-2021  | 16.0%   | 81.2%  | -30.0%  | 1.5   | 455.1  |
| 2020-2022  | -1.0%   | 81.2%  | 0.0%    | 1.5   | 480.5  |
| 2021-2023  | 24.0%   | 80.8%  | 23.0%   | 0.4   | 477.1  |
| 2022-2024  | -27.0%  | 78.8%  | -47.0%  | 0.3   | 458.4  |
| 2023-2025  | -61.0%  | 79.8%  | -126.0% | 1.2   | 296.7  |

**Analysis:**

*   **Significant Underperformance:** UNH has significantly underperformed the S&P 500, with a large negative divergence in cumulative returns.
*   **Low Relative Divergence:** The relative divergence being near the bottom of its range suggests the underperformance compared to the S&P 500 is nearing its worst levels within the observed period.
*   **Declining Alpha:** The Alpha values have declined significantly, particularly in recent periods, indicating that UNH is not generating excess returns compared to its benchmark (S&P 500).  In fact, it's significantly underperforming.
*   **Variable Beta:** The Beta values have fluctuated, suggesting varying levels of volatility relative to the market. Beta has increased, indicating recent increasing market sensitivity.
*   **High MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant potential for loss during the observed periods.
*   **Sharp decline in CAGR:** The Compounded Annual Growth Rate (CAGR) is declining sharply in the recent period (2023-2025) at -61%.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 327.42
*   **Last Market Data:** Price: 327.58, Previous Close: 324.8, Change: 0.86
*   **5-day SMA:** 332.498
*   **20-day SMA:** 329.988
*   **60-day SMA:** 340.108

**Analysis:**

*   **Price Below SMAs:** The current price is below all three Simple Moving Averages (5-day, 20-day, and 60-day). This *generally* suggests a short-term downtrend.  However, the 5-day SMA is approaching the 20-day, and both are significantly below the 60-day, highlighting the weakness in the short-term.

**3) RSI, PPO, and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 52.25 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.1151
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80) Dividend_2.21
*   **Recent (20 days) relative divergence change:** -2.3 (-): 단기하락 (Short-term decline)
*   **Expected Return (%):** -283.7
*   **Last-market change reflection:** Last market change of 0.86 indicates a small fluctuation issue (slight rebound)

**Analysis:**

*   **MRI Suggests Medium Risk:** The Market Risk Indicator (MRI) suggests a medium level of investment risk.
*   **Neutral RSI:** The RSI indicates the stock is not currently overbought or oversold.
*   **PPO Positive:** PPO (Price Percentage Oscillator) is slightly positive, meaning that the 12-period exponential moving average is above the 26-period exponential moving average.
*   **Hybrid Signal:** The hybrid signal leans towards a buy with a focus on safety, which seems contrary to other indicators and a high expected loss.
*   **Divergence Change Signals Short-Term Decline:** The negative change in relative divergence over the past 20 days confirms a recent downtrend.
*   **Extremely Negative Expected Return:** The expected return of -283.7% is extremely negative, suggesting a very pessimistic outlook for long-term investment compared to the S&P 500.

**4) Recent News & Significant Events:**

*   **December 24, 2025:** Amentum Stock Draws Fresh Buying Amid $14.4 Billion Revenue Year and 51% Stock Run
*   **December 23, 2025:** UnitedHealth Group (UNH) Stock After Hours Today (Dec. 22, 2025): Latest News, Analyst Forecasts, and What to Watch Before Tuesday’s Open
*   **December 21, 2025:** Where is UnitedHealth Group (UNH) Headed According to Wall Street?
*   **December 22, 2025:** UnitedHealth Group (UNH) Stock News, Forecasts and Analysis for Dec. 22, 2025: Independent Reviews, DOJ Scrutiny, and 2026 Guidance in Focus
*   **December 21, 2025:** UnitedHealth Group (UNH) Stock Week Ahead: Audit Overhaul, Trump’s Insurer Price Talks, and ACA Subsidy Deadline Drive the Outlook
*   **December 22, 2025:** UnitedHealth (UNH) Stock: Key Audit Updates, DOJ Risks, Earnings Outlook and Analyst Forecasts Before the Market Opens Dec. 22, 2025

**Analysis:**

*   **Mixed News:** The news headlines present a mixed picture. There are articles about analyst forecasts and what to watch, but also about "DOJ Scrutiny" and "Audit Overhaul," which could be concerning. The focus on 2026 guidance suggests investors are looking ahead for potential improvements or clarifications.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (~1.96 on a 1-5 scale)
*   **Opinions:** 25
*   **Target Price (Avg/High/Low):** 392.24 / 440.00 / 280.00
*   **Recent Rating Changes:** No information provided about specific changes.

**Analysis:**

*   **Positive Analyst Sentiment:** Despite the negative performance indicators, analysts, on average, have a "Buy" rating on the stock.
*   **Target Price Upside:** The average target price of 392.24 suggests a significant potential upside from the current price of 327.42. However, the low target price of 280.00 highlights a wide range of opinions and potential downside risk.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-10-28 | 2.59 | 113.16 B$   |
| 2025-08-11 | 3.76 | 111.62 B$   |
| 2025-05-07 | 6.90 | 109.58 B$   |
| 2024-11-04 | 6.56 | 100.82 B$   |
| 2025-10-28 | 6.56 | 100.82 B$   |

**Analysis:**

*   **Inconsistent EPS:** EPS (Earnings Per Share) is inconsistent and decreased over time.
*   **Revenue Growth:** Revenue has been steadily increasing, indicating growth in sales.
*   **Possible Data Error:** there are two records for '2025-10-28', suggest a potential data error.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $113.16B   | 18.24%       |
| 2025-06-30   | $111.62B   | 17.93%       |
| 2025-03-31   | $109.58B   | 21.70%       |
| 2024-12-31   | $100.81B   | 21.14%       |
| 2024-09-30   | $100.82B   | 22.84%       |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $95.79B    | 2.45%     |
| 2025-06-30   | $94.72B    | 3.60%     |
| 2025-03-31   | $95.04B    | 6.62%     |
| 2024-12-31   | $92.66B    | 5.98%     |
| 2024-09-30   | $94.53B    | 6.41%     |

**Analysis:**

*   **Revenue Growth Continues:** Revenue demonstrates continued growth, consistent with the previous earnings table.
*   **Decreasing Profit Margin:** Profit margin has decreased over the most recent quarters. This could indicate rising costs or pricing pressure.
*   **Equity Growth:** Equity has generally increased, indicating a strengthening financial base.
*   **Decreasing ROE:** Return on Equity (ROE) has significantly decreased in the most recent quarters, suggesting that the company is generating less profit from shareholders' equity.

**7) Comprehensive Analysis (Summary):**

UnitedHealth Group (UNH) presents a mixed picture:

*   **Negative Performance:** UNH has significantly underperformed the S&P 500 recently. All indicators are in the negative range.
*   **Declining Profitability:** Profit margins and ROE are declining, which is concerning.
*   **Revenue Growth:** Revenue growth remains a positive aspect.
*   **Analyst Optimism:** Analysts maintain a "Buy" rating, suggesting potential for future recovery, but this contrasts sharply with the numerical indicators, which indicate that recent analyst predictions have been wrong, or that they're factoring in a dramatic future turnaround.
*   **Market Indicators Mixed:** The MRI indicates moderate risk, and the RSI is neutral.
*   **News Cycle Concerns:** News articles highlight potential challenges like DOJ scrutiny and audit overhauls.
*   **Extremely Negative Expected Return:** The very negative expected return signals significant long-term risk relative to the broader market.
*   **Inconsistent EPS:** The inconsistent EPS and the decreasing EPS should be analyzed further.

**Overall Recommendation:**

Based on the provided data, **a cautious approach is warranted.** The significant underperformance, declining profitability, and negative expected return suggest substantial risks. While analysts maintain a "Buy" rating, this is contradicted by almost every other data point. Investors should carefully weigh these factors and conduct further due diligence before considering an investment in UNH. The news headlines also highlight potential near-term headwinds. The significant target price upside, suggested by analyst consensus, should be viewed with caution given the other negative indicators.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.